

# Resource Summary Report

Generated by [RRID](#) on Sep 10, 2026

## Diamyd Medical

RRID:SCR\_003930

Type: Tool

### Proper Citation

Diamyd Medical (RRID:SCR\_003930)

### Resource Information

**URL:** <http://www.diamyd.com/>

**Proper Citation:** Diamyd Medical (RRID:SCR\_003930)

**Description:** A diabetes company active in the field of pharmaceutical development. The Company develops the diabetes vaccine Diamyd with the active ingredient GAD, which has the potential to become a key piece of the puzzle of a future solution to prevent, treat or cure type 1 diabetes and other forms of diabetes. Diamyd Medical has independently pursued the development of the diabetes vaccine Diamyd to global Phase III trials, leading to one of Sweden's largest biotech agreements ever. The company has secured an exclusive license for a patent application for the specific combination therapy GAD plus the endogenous substance GABA, which has demonstrated favorable results in preclinical trials. The license also encompasses rights for the therapeutic use of GABA to treat diabetes and other inflammation-related disorders.

**Abbreviations:** DMYD B

**Synonyms:** Diamyd Medical AB

**Resource Type:** commercial organization

**Keywords:** pharmaceutical, drug development, drug

**Related Condition:** Type 1 diabetes, Diabetes

**Resource Name:** Diamyd Medical

**Resource ID:** SCR\_003930

**Alternate IDs:** nlx\_158298

**Record Creation Time:** 20220129T080221+0000

**Record Last Update:** 20260905T132511+0000

---

## Ratings and Alerts

No rating or validation information has been found for Diamyd Medical.

No alerts have been found for Diamyd Medical.

---

## Data and Source Information

**Source:** [SciCrunch Registry](#)

---

## Usage and Citation Metrics

We found 2 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [RRID](#) .

Carballido JM, et al. (2020) The Emerging Jamboree of Transformative Therapies for Autoimmune Diseases. *Frontiers in immunology*, 11, 472.

Steed J, et al. (2008) Antigen presentation of detergent-free glutamate decarboxylase (GAD65) is affected by human serum albumin as carrier protein. *Journal of immunological methods*, 334(1-2), 114.